Results 131 to 140 of about 8,676,773 (167)

1009 Effectiveness and Satisfaction with Low-Sodium Oxybate as Described by Adults Living with Narcolepsy: LYRICAL Survey & Interview Findings

SLEEPJ
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved by the US Food and Drug Administration to treat cataplexy or excessive daytime sleepiness (EDS) in patients aged ≥7 years with narcolepsy.
Caroleen Drachenberg, Meagan Farrell, Jennifer D’Souza, Emily Kim, Meaghan Lawrence, Christina Graham, Marisa Whalen, Jessica Alexander, Silky Beaty, Sarah Markt, Laura Herpel   +10 more
openaire   +1 more source

0725 Improvements in Sleep Inertia with Low-Sodium Oxybate Treatment in Participants with Narcolepsy Type 1 and Type 2 in the DUET Study

SLEEPJ
Abstract Introduction Sleep inertia (characterized by profound difficulty waking up with grogginess, disorientation, and cognitive impairment immediately after awakening) is a core idiopathic hypersomnia symptom and may also be experienced by individuals with narcolepsy.
Deborah Nichols, Logan Schneider, David Plante, Jing Dai, Teresa Steininger, Marisa Whalen, Alyssa Cairns, Chad Ruoff, Hans Van Dongen   +8 more
openaire   +1 more source

0749 Effectiveness and Safety of Low-Sodium Oxybate by Patient-Reported Long Sleep Need in DUET Study Participants with Idiopathic Hypersomnia

SLEEPJ
Abstract Introduction Low-sodium oxybate (LXB; Xywav®), the only FDA-approved treatment for idiopathic hypersomnia in adults, was evaluated in the phase 4, open-label DUET study (NCT05875974). This post-hoc analysis evaluated subgroups of participants with idiopathic hypersomnia stratified by ...
David Plante, Chad Ruoff, Logan Schneider, Deborah Nichols, Teresa Steininger, Alyssa Cairns, Jing Dai, Marisa Whalen, Yves Dauvilliers   +8 more
openaire   +1 more source

1010 Effectiveness and Satisfaction with Low-Sodium Oxybate as Described by Adults Living with Idiopathic Hypersomnia: LYRICAL Survey & Interview Findings

SLEEPJ
Abstract Introduction Low-sodium oxybate (LXB; Xywav®) is approved in the US for the treatment of idiopathic hypersomnia (IH) in adults. LYRICAL, a longitudinal, mixed methods study, examined the real-world treatment experience of US adults to provide details on the impact of LXB on a range of ...
Caroleen Drachenberg, Meagan Farrell, Jennifer D’Souza, Emily Kim, Meaghan Lawrence, Christina Graham, Marisa Whalen, Jessica Alexander, Silky Beaty, Sarah Markt, Laura Herpel   +10 more
openaire   +1 more source

The Treatment of Parkinson’s Disease with Sodium Oxybate

Current Molecular Pharmacology, 2023
Mortimer Mamelak
exaly  

Long-term Safety During a Clinical Trial of Low-Sodium Oxybate in Participants With Narcolepsy With Cataplexy (P5-13.006)

Neurology, 2023
Richard Bogan, Nancy Foldvary-Schaefer, Roman Skowronski, Abby Chen, Michael Thorpy   +4 more
openaire   +1 more source

Insights from real-world and interventional studies of patients transitioning from sodium oxybate to low-sodium oxybate

Sleep Medicine
W. Macfadden, A.M. Husain, P.C. Zee, D.S. Fuller, S. Candler, C. Bae   +5 more
openaire   +1 more source

Sleep, Narcolepsy, and Sodium Oxybate

Current Neuropharmacology, 2022
Mortimer Mamelak
exaly  

Blood pressure changes after treatment with low-sodium oxybate in oxybate-naive patients with narcolepsy or idiopathic hypersomnia: a post hoc analysis

Sleep Medicine
W. Macfadden, S. Candler, D.S. Fuller, T.J. Measey, W.B. White   +4 more
openaire   +1 more source

Sleep Architecture With Low-Sodium Oxybate Treatment in Narcolepsy: Results From the DUET Study

Sleep Medicine
C.M. Ruoff, L.D. Schneider, R.B. Sangal, D.A. Nichols, T.L. Steininger, D.S. Fuller, M.T. Kirby, J.K. Alexander, E. Mignot   +8 more
openaire   +1 more source